10x Genomics EBITDA
Cos'è EBITDA di 10x Genomics?
EBITDA di 10x Genomics, Inc. è -$117.15
Qual è la definizione di EBITDA?
L'EBITDA è il reddito di una società prima di interessi, imposte, deprezzamenti e ammortamenti ed è una misura contabile calcolata utilizzando gli utili netti di una società, prima che vengano sottratti interessi passivi, imposte, ammortamenti e ammortamenti come proxy della redditività corrente di un'azienda.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA di aziende nel Health Care settore su NASDAQ rispetto a 10x Genomics
Cosa fa 10x Genomics?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Aziende con ebitda simili a 10x Genomics
- B. Riley Inc ha EBITDA di -$118.65
- B. Riley Inc ha EBITDA di -$118.65
- Freeline Therapeutics plc ha EBITDA di -$118.33
- TFG International ha EBITDA di -HKD$118.24
- New Century Healthcare Co ha EBITDA di -¥118.18
- Rudra Global Infra Products ha EBITDA di -₨117.27
- 10x Genomics ha EBITDA di -$117.15
- Radaan Mediaworks India ha EBITDA di -₨117.09
- Palash Securities ha EBITDA di -₨116.97
- Progenity ha EBITDA di -$116.40
- Syros Pharmaceuticals ha EBITDA di -$116.00
- China Yurun Food ha EBITDA di -HKD$114.97
- Ashok Alco-Chem ha EBITDA di -₨114.91